Sulfoglycodendrimer Therapeutics for HIV‐1 and SARS‐CoV‐2

Hexavalent sulfoglycodendrimers (SGDs) are synthesized as mimics of host cell heparan sulfate proteoglycans (HSPGs) to inhibit the early stages in viral binding/entry of HIV‐1 and SARS‐CoV‐2. Using an HIV neutralization assay, the most promising of the seven candidates are found to have sub‐micromol...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Adv Ther (Weinh)
Autors principals: Wells, Lauren, Vierra, Cory, Hardman, Janee’, Han, Yanxiao, Dimas, Dustin, Gwarada‐Phillips, Lucia N., Blackeye, Rachel, Eggers, Daryl K., LaBranche, Celia C., Král, Petr, McReynolds, Katherine D.
Format: Artigo
Idioma:Inglês
Publicat: John Wiley and Sons Inc. 2021
Matèries:
Full Papers
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7995185/
https://ncbi.nlm.nih.gov/pubmed/33786368
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/adtp.202000210
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars